Category X—No reports describing the use of lorcaserin in human pregnancy have been located. The animal reproduction data suggest moderate risk, but the absence of human pregnancy experience prevents a better assessment of the embryo-fetal risk. However, the manufacturer classifies the drug as contraindicated in pregnancy because weight loss offers no potential benefit to a pregnant woman and may result in fetal harm.
No reports describing the use of lorcaserin during human lactation have been located. The molecular weight (about 197 for the free base), moderate (about 70%) plasma protein binding, and the long (about 11 hours) plasma half-life suggest that the drug will be excreted into breast milk. The effect of the exposure on a nursing infant is unknown.
The effect of lorcaserin in geriatric populations is unknown, as most patients in the three published clinical trials were 65 years of age or younger.12 No dose adjustments should be made based solely on age.
No dose adjustment necessary in patients with mild impairment. Use with caution in patients with moderate impairment. Not recommended in patients with severe impairment or end-stage renal disease.
No dose adjustment necessary in patients with mild to moderate impairment.